The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.

Citing Articles

Case report: single-cell transcriptome sequencing reveals the clonal origin of mature plasmacytoid dendritic cell proliferation in early T-cell precursor lymphoblastic leukemia.

Zhang L, Lu Y, Jiang J, Wu G Ann Hematol. 2025; .

PMID: 40085211 DOI: 10.1007/s00277-025-06301-5.

Case Report: Coexistence of Rosai-Dorfman disease and B-cell acute lymphoblastic leukemia in an adolescent.

Jenabzadeh A, Binesh F, Shahbaz A, Alavi S Front Pediatr. 2025; 13:1529833.

PMID: 40079030 PMC: 11897000. DOI: 10.3389/fped.2025.1529833.

Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia.

Liu Q, Yang J, Lv L, Zhang X, Li M, Xu L Front Immunol. 2025; 16:1525110.

PMID: 40079007 PMC: 11897025. DOI: 10.3389/fimmu.2025.1525110.

Editorial: MDS: new scientific and clinical developments.

Blum S, Symeonidis A, Germing U Front Oncol. 2025; 15:1568681.

PMID: 40078185 PMC: 11896990. DOI: 10.3389/fonc.2025.1568681.

Acute Leukemia of Ambiguous Lineage: Diagnosis and Evaluation by Flow Cytometry.

Fuda F, Chen W Cancers (Basel). 2025; 17(5).

PMID: 40075717 PMC: 11898493. DOI: 10.3390/cancers17050871.

References

Uttley L, Indave B, Hyde C, White V, Lokuhetty D, Cree I . Invited commentary-WHO Classification of Tumours: How should tumors be classified? Expert consensus, systematic reviews or both?. Int J Cancer. 2020; 146(12):3516-3521. PMC: 7818407. DOI: 10.1002/ijc.32975. View

Salto-Tellez M, Cree I . Cancer taxonomy: pathology beyond pathology. Eur J Cancer. 2019; 115:57-60. DOI: 10.1016/j.ejca.2019.03.026. View

Bruford E, Antonescu C, Carroll A, Chinnaiyan A, Cree I, Cross N . HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. Leukemia. 2021; 35(11):3040-3043. PMC: 8550944. DOI: 10.1038/s41375-021-01436-6. View

Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman P, Mar B . Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-98. PMC: 4306669. DOI: 10.1056/NEJMoa1408617. View

Beck D, Ferrada M, Sikora K, Ombrello A, Collins J, Pei W . Somatic Mutations in and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med. 2020; 383(27):2628-2638. PMC: 7847551. DOI: 10.1056/NEJMoa2026834. View

Steensma D, Bejar R, Jaiswal S, Lindsley R, Sekeres M, Hasserjian R . Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015; 126(1):9-16. PMC: 4624443. DOI: 10.1182/blood-2015-03-631747. View

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F . Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 2016; 128(16):2096-2097. PMC: 5341483. DOI: 10.1182/blood-2016-07-728766. View

Hochhaus A, Larson R, Guilhot F, Radich J, Branford S, Hughes T . Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017; 376(10):917-927. PMC: 5901965. DOI: 10.1056/NEJMoa1609324. View

Kalmanti L, Saussele S, Lauseker M, Muller M, Dietz C, Heinrich L . Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015; 29(5):1123-32. DOI: 10.1038/leu.2015.36. View

10.

Wang W, Cortes J, Tang G, Khoury J, Wang S, Bueso-Ramos C . Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016; 127(22):2742-50. PMC: 4915795. DOI: 10.1182/blood-2016-01-690230. View

11.

Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F . Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017; 129(24):3227-3236. DOI: 10.1182/blood-2017-01-761999. View

12.

Rumi E, Boveri E, Bellini M, Pietra D, Ferretti V, SantAntonio E . Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget. 2017; 8(60):101735-101744. PMC: 5731910. DOI: 10.18632/oncotarget.21594. View

13.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M . Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011; 29(23):3179-84. DOI: 10.1200/JCO.2010.34.5298. View

14.

Szuber N, Finke C, Lasho T, Elliott M, Hanson C, Pardanani A . CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. Blood Cancer J. 2018; 8(2):21. PMC: 5814430. DOI: 10.1038/s41408-018-0058-7. View

15.

Pardanani A, Lasho T, Laborde R, Elliott M, Hanson C, Knudson R . CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013; 27(9):1870-3. PMC: 4100617. DOI: 10.1038/leu.2013.122. View

16.

Pardanani A, Lasho T, Wassie E, Finke C, Zblewski D, Hanson C . Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. Leukemia. 2016; 30(9):1924-6. DOI: 10.1038/leu.2016.73. View

17.

Cross N, Hoade Y, Tapper W, Carreno-Tarragona G, Fanelli T, Jawhar M . Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia. 2018; 33(2):415-425. PMC: 6365490. DOI: 10.1038/s41375-018-0342-3. View

18.

Wang S, Hasserjian R, Tam W, Tsai A, Geyer J, George T . Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017; 102(8):1352-1360. PMC: 5541870. DOI: 10.3324/haematol.2017.165340. View

19.

Fang H, Ketterling R, Hanson C, Pardanani A, Kurtin P, Chen D . A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience. Am J Clin Pathol. 2018; 150(5):421-431. DOI: 10.1093/ajcp/aqy064. View

20.

Reiter A, George T, Gotlib J . New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood. 2020; 135(16):1365-1376. DOI: 10.1182/blood.2019000932. View